Cannabis Stocks Slip 2% as Psychedelic Names Rally 4% on Trial News
Cannabis sector equities, including Canopy Growth and Aurora Cannabis, retreated about 2% over the past week following indications of renewed regulatory scrutiny. In contrast, psychedelic-focused stocks such as Compass Pathways and MindMed outpaced peers with gains near 4% after late-stage clinical trial updates.
1. Cannabis Sector Performance
Major cannabis producers, led by Canopy Growth and Aurora Cannabis, saw share prices decline roughly 2% over the past five trading days. Analysts cited upcoming federal hearings and slower-than-expected retail sales growth in key U.S. markets as headwinds for the group.
2. Psychedelic Sector Outperformance
Companies developing psilocybin and MDMA therapies, including Compass Pathways and MindMed, delivered week-to-date gains near 4% after announcing positive late-stage trial data. Investor focus shifted toward mental health biotechs, driving sector ETFs 1.8% higher.